Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioStem TechnologiesBSEM +3.26%36 EV-to-EBITDA is 3.23 as of Aug. 02, 2026. GuruFocus rates BSEM with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 416 Biotechnology companies, BioStem Technologies ranks better than 67.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioStem Technologies's enterprise value is $32.5 Mil.
BioStem Technologies's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $10.1 Mil. Therefore, BioStem Technologies's EV-to-EBITDA for today is 3.23.
The historical rank and industry rank for BioStem Technologies's EV-to-EBITDA or its related term are showing as below:
BSEM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.98 Med: -8.35 Max: 74.61
Current: 3.23
During the past 13 years, the highest EV-to-EBITDA of BioStem Technologies was 74.61. The lowest was -33.98. And the median was -8.35.
BSEM's EV-to-EBITDA is ranked better than 67.31% of 416
companies
in the Biotechnology industry
Industry Median: 11.905
vs BSEM: 3.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioStem Technologies's PE Ratio (TTM) for today is calculated as:
BioStem Technologies's share price for today is $3.31418.
BioStem Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.710.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for BioStem Technologies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioStem Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's EV-to-EBITDA falls into.
BioStem Technologies's current Enterprise Value is $32.5 Mil.
BioStem Technologies's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (BSEM) has a EV-to-EBITDA of 3.23 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioStem Technologies. According to the industry distribution chart, BioStem Technologies ranks #136 out of 416 companies in the Biotechnology industry, placing it in the top 32.7%.
Is BioStem Technologies' EV-to-EBITDA too high?
BioStem Technologies' current EV-to-EBITDA is 3.23. The Biotechnology industry median EV-to-EBITDA is 11.91. BioStem Technologies' value of 3.23 is 72.9% below this industry median. Based on the distribution chart, BioStem Technologies ranks #136 out of 416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioStem Technologies has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' EV-to-EBITDA compare to RNTX and SPRO?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #136 out of 416 companies for EV-to-EBITDA. This puts BioStem Technologies in the upper half of its industry. The industry median EV-to-EBITDA is 11.91. BioStem Technologies' value of 3.23 is 72.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.91, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioStem Technologies's current EV-to-EBITDA of 3.23 is 72.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioStem Technologies. For the Biotechnology industry, the median EV-to-EBITDA is 11.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current EV-to-EBITDA is 3.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (BSEM) has a current EV-to-EBITDA of 3.23. The current EV-to-EBITDA is 3.23 and 72.9% below the Biotechnology industry median of 11.91. BioStem Technologies' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current EV-to-EBITDA is 3.23 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
36GF Score
Get the complete analysis for BSEM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
